Dr. Westerhout oversees the CVC Clinical Trial Statistics team, and provides consultation on the design and analysis of clinical trials and observational studies. Her research interests include therapeutic treatment effects (e.g., composite endpoints) in randomized clinical trials. She also advises the Board and Faculty on the strategic directions of the CVC and their implementation.
Dr. Westerhout completed a MSc in epidemiology at the University of Alberta in 2001 and a PhD in clinical cardiovascular epidemiology at Erasmus University (Rotterdam, the Netherlands) in 2007. She is a co-founder of the BALSAM (Biomedical AnaLytics Studio And Methods unit) at the University of Alberta, and is a member of the editorial board of the American Heart Journal.
